NQO1 and obesity due to melanocortin 4 receptor deficiency: Pharmacological activation of NADH oxidation by NQO1 through administration of the substrate β-lapachone has been associated with amelioration of obesity along with glucose intolerance, dyslipidemia, and fatty liver [41,42].